GH peptides before and after: the gym-floor story vs what studies measured

Scroll any physique feed and the GH peptide story arrives as a before-and-after: a softer “before,” a fuller and leaner “after,” and a caption crediting CJC-1295, ipamorelin, or a blend of the two. This page sets that gym-floor story against what controlled studies actually measured, growth hormone (GH), IGF-1, lean mass, body water, fat and strength, and then covers the side effects of peptides in bodybuilding that both trials and users report. Everything here is sourced to the primary clinical literature rather than vendor copy. For the underlying pharmacology of the two peptides most people mean, see our explainer on what CJC-1295 and ipamorelin actually do, and for the wider category, our guide to peptides for muscle growth.

What do GH peptides realistically do for physique?

Realistically, growth-hormone peptides do one thing that is well documented and one thing that is not. The documented part is pharmacological: peptides such as CJC-1295 and ipamorelin raise the body’s own growth hormone and, downstream, insulin-like growth factor 1 (IGF-1). In the human pharmacology trial of the long-acting form, a single injection of CJC-1295 produced “dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 [days] or more” and raised IGF-I “by 1.5- to 3-fold for 9-11 [days]” (Teichman et al., 2006). Ipamorelin was characterized as a selective GH secretagogue that “displays high GH releasing potency” (Raun et al., 1998). So the biomarkers move, that much is real.

The undocumented part is the part the marketing sells: that raising those hormones translates into visible muscle, fat loss, or better recovery. There is no published human trial showing that CJC-1295 or ipamorelin builds muscle or improves body composition, and ipamorelin’s one completed human efficacy trial, for postoperative bowel recovery, not physique, did not beat placebo (Beck et al., 2014). In plain terms, the evidence level for these peptides is short human trials that measured hormones or unrelated outcomes, not bodies. A hormone associated with growth going up on a lab report is a genuinely weaker statement than “people who took this measurably changed their physique in a controlled comparison.”

Peptides for muscle growth before and after: the myth vs what studies measured

The honest way to read a before-and-after post is to ask what a controlled study would have measured over the same stretch. Because the peptides have no body-composition trials of their own, the closest measured evidence is growth hormone itself, the hormone the peptides are trying to raise. The table pairs the claims that circulate online with what the studies actually recorded.

Before-and-after claims about GH peptides set against measured outcomes. The peptide trials measured GH and IGF-1 only; the body-composition rows come from trials of growth hormone itself. Educational information, not a recommendation to use any peptide.

Attribute	Claim seen online	What the study measured	Source
GH and IGF-1	The peptide is working because my levels went up	CJC-1295 raised GH 2- to 10-fold and IGF-1 1.5- to 3-fold in healthy adults; muscle and fat were not the outcomes	Teichman et al., 2006
Lean mass	Packed on lean muscle in weeks	Pooled GH trials in fit young adults: lean body mass up 2.1 kg vs no GH, while strength and exercise capacity did not seem to improve	Liu et al., 2008
Water	Fuller, harder look in the after photo	In an 8-week randomized trial, GH increased lean body mass through an increase in extracellular water	Meinhardt et al., 2010
Muscle tissue	The new size is real muscle	With 12 weeks of lifting, GH raised fat-free mass and body water more than placebo, but not thigh muscle protein synthesis, limb size or strength	Yarasheski et al., 1992
Fat	Leaner in the after shot	GH significantly reduced fat mass in recreational athletes	Meinhardt et al., 2010
Strength and performance	Lifts went up	Sprint capacity rose 3.9% and was gone 6 weeks after stopping; endurance, dead lift strength and jump height did not significantly change	Meinhardt et al., 2010; Hermansen et al., 2017
Cause of the change	The peptide did this	No controlled peptide data; several people posting physique transformations were also running many other compounds at once	Community Insights, July 2026

Three findings explain most of the gap between the photo and the data. First, the lean mass that GH adds is partly water: the Australian randomized trial in 96 recreational athletes found that GH “increased lean body mass through an increase in extracellular water” and “significantly reduced fat mass,” which is exactly the fuller, leaner change a camera rewards (Meinhardt et al., 2010). Second, that added mass does not behave like trained muscle. In young men lifting for 12 weeks, fat-free mass and total body water rose more with GH than placebo, but “quadriceps muscle protein synthesis rate, torso and limb circumferences, and muscle strength did not increase more in the GH-treated group,” leading the authors to conclude the extra mass was “probably due to an increase in lean tissue other than skeletal muscle” (Yarasheski et al., 1992). Third, the one performance gain in the athlete trial, a 3.9% rise in sprint capacity, “was not maintained 6 weeks after discontinuation of the drug,” while endurance, strength and jump height did not significantly change (Meinhardt et al., 2010).

Two more things make peptide before-and-after posts hard to interpret. The peptide trials themselves never weighed a muscle: CJC-1295’s human study measured blood GH and IGF-1 (Teichman et al., 2006). And the posts are rarely a single-variable experiment. Our Community Insights summary of 17 public X posts on CJC-1295 (July 13 to 19, 2026) noted that several people reporting physique transformations were also running many other compounds at once, which makes any one peptide’s effect impossible to isolate. Those are anecdotes, not evidence, but they describe the photos most readers are seeing.

Do GH peptides build muscle, or is it mostly water?

The most useful evidence on this question does not come from the peptides at all, it comes from growth hormone itself. If GH does not reliably build functional muscle in healthy people, a peptide that produces less GH than injecting GH directly is unlikely to do better. And the GH evidence in healthy adults is sobering. Tesamorelin’s large trials measured fat and IGF-1 rather than strength; our page on whether tesamorelin builds muscle walks through what those trials measured.

A systematic review in the Annals of Internal Medicine pooled the controlled trials of GH in healthy, mostly young participants. It found that “lean body mass increased in growth hormone recipients compared with participants who did not receive growth hormone (increase, 2.1 kg [95% CI, 1.3 to 2.9 kg]),” but that “strength and exercise capacity did not seem to improve.” Its bottom line was blunt: “Claims that growth hormone enhances physical performance are not supported by the scientific literature. Although the limited available evidence suggests that growth hormone increases lean body mass, it may not improve strength; in addition, it may worsen exercise capacity and increase adverse events” (Liu et al., 2008). A later meta-analysis reached the same shape of conclusion: “GH administration elicits significant changes in body composition, but does not increase either muscle strength or aerobic exercise capacity in healthy, young subjects” (Hermansen et al., 2017).

The gap between “lean body mass went up” and “strength did not” is the whole story. The trials that looked directly found the extra lean mass tracked extracellular water (Meinhardt et al., 2010) and tissue other than skeletal muscle (Yarasheski et al., 1992). So the honest answer to “do they build muscle or is it water” is that even for GH itself the measurable gain in healthy people behaves far more like fluid than like muscle, and for the peptides there is no body-composition trial at all.

Side effects of peptides in bodybuilding: what GH peptides cause

The side effects of peptides in bodybuilding that are actually documented are the growth-hormone ones, because the peptides raise the same hormones as GH therapy, and they are not nothing. Across the GH literature, the most common adverse effects cluster around fluid retention. A large safety analysis of GH-treated adults reported that “side effects of GH replacement are often related to fluid retention, in particular during initiation and dose titration,” with arthralgia (joint pain) and peripheral edema (swelling) the two most frequently reported events, along with muscle pain, carpal tunnel syndrome, and paresthesia, numbness and tingling (Johannsson et al., 2022). In the systematic review of healthy people, “growth hormone-treated participants more frequently experienced soft tissue edema and fatigue than did those not treated with growth hormone” (Liu et al., 2008). For a GH peptide with an FDA label of its own, see tesamorelin side effects.

Three reported effects are worth naming specifically because they follow directly from the mechanism:

• Water retention and swelling. Fluid retention is the signature effect of raising GH activity, and it is the most likely explanation for the “lean mass” bump that is not matched by strength (Liu et al., 2008; Meinhardt et al., 2010).
• Joint aches and carpal-tunnel-type numbness and tingling. The same fluid shifts drive arthralgia and compression of the median nerve at the wrist; carpal tunnel syndrome and paresthesia are both recognized in the adult GH safety data (Johannsson et al., 2022).
• Effects on blood sugar and insulin sensitivity. GH is a counter-regulatory hormone that opposes insulin, so raising it can nudge glucose upward. The adult safety analysis found a small median rise in fasting glucose and a low rate of new type 2 diabetes on treatment (Johannsson et al., 2022), a modest signal, but a real one in the direction of reduced insulin sensitivity.

Two honest caveats sit on top of that list. First, the peptides themselves have barely been studied for safety in humans: the trials that exist ran for days to weeks in small groups, so “well tolerated” in those studies is not a long-term safety profile, and anything marketed as “side-effect-free” is overreading a handful of brief studies. Second, the GH data above come from pharmaceutical-grade growth hormone given under supervision. A peptide vial of unknown origin is a different situation, which is the subject of the next section.

The side effect the label hides: what’s actually in the vial

Beyond the pharmacology, there is a supply-chain risk that no dosing discussion captures. Peptides sold online as “research use only” are not made to pharmaceutical standards, and their quality depends entirely on the seller. A laboratory analysis of the falsified peptide drugs most frequently encountered on one national market documented “a high variation in amount of drugs per unit,” “a low purity (ranging between 5% and 75% for cysteine containing peptides),” and contamination with toxic elements, arsenic at levels “up to ten times the ICH toxicity limit for parenteral drugs,” and lead in at least one sample (Janvier et al., 2018). For something injected repeatedly, an unverified product stacked on top of an unproven compound is arguably the most important “side effect” of all, and one that no protocol can dose around. Who made the product, and whether it was tested for identity, potency and sterility, matters as much as the molecule.

What side effects do people report from CJC-1295 and ipamorelin?

In public posts, the side effects people describe line up closely with the growth hormone literature above: flushing, sleep changes, and worry about blood sugar. Our Community Insights summaries of public posts on X (17 posts on CJC-1295 from July 13 to 19, 2026, and 16 on ipamorelin from July 15 to 16, 2026) found these recurring reports; they are anecdotes, not evidence:

• Flushing. One poster describes intense facial flushing early on that faded after they lowered the dose.
• Sleep. Another says CJC-1295 wrecked their sleep, leaving them with bloodshot eyes and feeling exhausted, and an ipamorelin poster reports sleep getting worse rather than better, the opposite of a common marketing claim.
• Insulin and IGF-1. Insulin resistance and high IGF-1 are described as the two most cited fears around long-term GH peptide use; one poster argues they are overstated, while others raise concerns that the long-acting DAC form, by keeping GH elevated continuously, may add to that risk.

These reports cannot tell you how common any effect is, but they point the same way as the trial data: the effects people notice are the ones raising growth hormone is known to produce, while the muscle-building effect is the part nobody has measured. The trial-by-trial list is in CJC-1295 and ipamorelin side effects, and the timing question is in how long CJC-1295 and ipamorelin take to work.

Are muscle peptides like CJC-1295 and ipamorelin safe?

Their long-term safety is unknown, because it has not been studied. In the human CJC-1295 trial, “no serious adverse reactions were reported” and the peptide was “relatively well tolerated,” but those trials followed healthy adults for 28 to 49 days, not years (Teichman et al., 2006). What is known comes from growth hormone itself, where fluid retention, joint pain, carpal tunnel symptoms and higher glucose are the recognized costs (Johannsson et al., 2022). Unregulated vials add a separate risk of wrong doses and contaminants (Janvier et al., 2018).

What are the downsides of taking GH peptides?

The downsides are the predictable effects of more GH activity, a missing long-term safety record, uncertain product quality, and results that may be mostly water. Growth hormone trials in healthy adults report more soft tissue swelling and fatigue than in untreated participants (Liu et al., 2008), and adult GH safety data add joint pain, numbness and tingling, and small rises in glucose (Johannsson et al., 2022). The physique payoff, meanwhile, has never been measured for the peptides. Our peptides for muscle growth guide covers the same downsides across other compounds.

Do GH peptides really work for muscle building?

There is no controlled evidence that they do. CJC-1295 raised GH and IGF-1 in healthy adults (Teichman et al., 2006), and ipamorelin released GH in rat and pig studies (Raun et al., 1998), but no human trial has measured muscle or strength outcomes for either. Growth hormone itself, injected directly, raised lean mass largely through water and non-muscle tissue without improving strength, even when paired with resistance training (Liu et al., 2008; Meinhardt et al., 2010; Yarasheski et al., 1992). For how that compares with anabolic steroids, see GH peptides vs anabolic steroids.

Realistic expectations vs the marketing, side by side

The table contrasts what GH-axis peptide marketing tends to imply with what the primary literature actually supports. It is not a list of features to weigh; it is a reality check.

What GH peptide marketing implies versus what the primary clinical literature supports. Evidence reflects the cited growth-hormone and peptide studies; this is educational information, not a recommendation to use any peptide.

Attribute	What the marketing implies	What the evidence supports
Builds visible muscle	Adds lean muscle while you sleep	No human body-composition trial for the peptides; GH raises ’lean mass’ that behaves like fluid, with no strength gain
Improves strength / performance	Better gym performance and recovery	GH did not improve strength or exercise capacity in healthy people; may worsen exercise capacity
Side-effect profile	Clean, ’side-effect-free’	Fluid retention, swelling, joint aches, carpal-tunnel-type numbness/tingling, glucose/insulin effects reported for GH
What was actually measured	Real-world muscle and fat results	Blood levels of GH and IGF-I over days, biomarkers, not outcomes
Product you receive	Pharmaceutical-grade peptide	Quality depends on the source; ’research use only’ vials tested in one market showed purity and contamination problems

Why realistic expectations matter

Realistic expectations matter because the gap between the promise and the evidence is exactly where money and health get spent. If you expect a peptide to build muscle and it instead raises a hormone and holds some water, you may misread scale-weight fluid as progress, keep injecting a product chasing a result that was never demonstrated, and skip the training and nutrition variables that actually move body composition. For the broader physique context, see our growth hormone peptide overview for physique goals.

A realistic expectation is not a cynical one. It is simply the version that survives contact with the primary literature: an interesting mechanism, thin human proof, a real and predictable side-effect profile borrowed from GH therapy, and a product-quality question that depends on where the peptide comes from. Bring the goal, muscle, recovery, body composition, rather than a product name, and it becomes a decision you can make on evidence instead of on a label written to reassure you.

Status (CJC-1295 and ipamorelin): Not FDA-approved; sold by some telehealth providers as a compounded prescription. What this status means.

Educational information only, not medical advice, and not an endorsement of non-medical peptide use. Every clinical statement on this page is sourced to the peer-reviewed literature linked above; the community summary reflects public posts on X analyzed in July 2026. Updated October 12, 2026. This page is drafted with AI assistance and fact-checked against the cited primary sources before publication.